Monday, September 14, 2026

Inside Kim Jong Un’s Talks with Xi: A Closer Look at Their Diplomatic Dance

Kim Jong Un met with Xi Jinping in Beijing, discussing bilateral ties and expressing gratitude for China's hospitality.

North Korea Celebrates Longtime Ally in Japan—But Signals Shift in Tone

North Korea commemorates Chongryon's 70th anniversary, but Kim Jong Un's letter notably omits unification, raising concerns.

Couldn’t Recognize Mariah Carey: Olympic Broadcast Chief Resigns

The broadcasting head responsible for multiple errors during the 2026 Milan-Cortina Winter Olympics opening ceremony has resigned.

Tag: immuno-oncology

North KoreaKoreaKimMilitaryAISouth Koreamarketrelationsdevelopment

AbClon Secures Japanese Patent for Dual-Antibody Cancer Drug AM105: What This Means for Global Markets

AbClon has completed the registration of a Japanese patent for its next-generation dual antibody immuno-oncology candidate AM105.

Celltrion’s CT-P51: Will This Keytruda Biosimilar Disrupt the 44 Billion USD Cancer Drug Market?

Celltrion has applied for approval of its biosimilar CT-P51 for the global blockbuster immuno-oncology drug Keytruda (pembrolizumab).

ABL Bio to Launch Global Phase 3 Trial of Gastric Cancer Drug Givastomig This Year at BIO USA

ABL Bio plans a Phase 3 trial for gastric cancer therapy Givastomig, targeting a $2.5 billion market opportunity.

CT-P72/ABP-102: The Next Big Breakthrough in HER2 Cancer Treatment?

Celltrion's CT-P72/ABP-102 shows strong efficacy against HER2 tumors, promising for treating various cancers with reduced toxicity.

AACR 2026 Highlighted Shift Toward Patient-Centered Cancer Drug Development, Foundation Says

Cancer research is evolving towards patient-centered outcomes, integrating data and technology for better treatments, as noted at AACR 2026.

GI-101A: Breakthrough Immuno-Oncology Drug Set for ASCO 2026 Presentation

GI Innovation's GI-101A will be presented at ASCO 2026, highlighting its clinical potential and significance in oncology.

How Celltrion Plans to Cut Biologics Development Costs by 25% Amid FDA Regulation Changes

Celltrion is optimistic about enhanced competitiveness due to eased biosimilar regulations by the FDA, expecting significant cost reductions.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.